Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

Inclusion criteria - Signed willing to sign a consent form - Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb. - Indication of full-dose anticoagulant therapy for at least 3 months. - Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis - Life expectancy more than 3 months - Social security affiliation Who Should NOT Join This Trial: - Unable to give willing to sign a consent form - Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg - Anticoagulation for more than 5 days prior to randomization - Active pregnancy or expected pregnancy or no effective contraception - Isolated distal deep vein thrombosis - Antiplatelet therapy prescribed for primary prevention of cardiovascular disease - Indication to maintain a dual-antiplatelet therapy. - Triple positive antiphospholipid syndrome, with arterial thrombosis - Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases Always talk to your doctor about whether this trial is right for you.